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Colloidal systems prepared from carbohydrates are subject of intense research due to their 10 
potential to enhance drug permeability through biological membranes, however their 11 
characteristics and performance are never compared directly.  Here we report the results of a 12 
comparative investigation of a series of butylglyceryl-modified polysaccharides (chitosan, guar 13 
gum, and pullulan) that were formulated into nanoparticles and loaded with a range of model 14 
actives (Doxorubicin, Rhodamine B, Angiotensin II). Butylglyceryl-modified guar gum and 15 
corresponding pullulan nanocarriers were more stable at physiological pH compared to those 16 
obtained from modified chitosan, and studies of the in-vitro interactions with mouse brain 17 
endothelial cells (bEnd3) indicated an increased biological membrane permeability and lack of 18 
toxicity at application-relevant concentrations. No significant haemolytic effect was observed, 19 
and confocal microscopy and flow cytometry studies confirmed the efficient cellular uptake 20 
and cytoplasmic localisation of NPs. Most promising characteristics for brain drug delivery 21 
applications were demonstrated by butylglyceryl pullulan nanocarriers. 22 
 23 
 24 




1. Introduction 29 
 A significant number of brain disorders are considered responsible for the rising 30 
morbidity and mortality observed in both developed and developing countries  (Raggi & 31 
Leonardi, 2019), but real progress in the treatment of many neurological disorders has been 32 
long hindered by the inability of most drugs to enter the brain – despite recent technological 33 
advances, the blood-brain barrier (BBB) continues to represent a major challenge (Aikaterini 34 
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Lalatsa & Barbu, 2016). In concerted efforts to enhance drug concentration in the brain, many 35 
strategies have been considered, however it has been found that the benefits registered with 36 
several invasive methods come at the rather high cost of harmful side effects (Aikaterini 37 
Lalatsa, Schatzlein, & Uchegbu, 2014). Current research tends therefore to concentrate on non-38 
invasive strategies, with the use of colloidal drug carriers as a most promising approach for 39 
systemic brain delivery (Godfrey et al., 2018; Lu et al., 2014). 40 
Among the carbohydrates investigated, of particular interest are polysaccharides: they 41 
are highly stable, non-toxic, biodegradable, possess hydrophilic moieties that mediate non-42 
covalent interactions with biological tissues (Hervé, Ghinea, & Scherrmann, 2008), and can be 43 
converted into amphiphilic materials that self-assemble into colloidal carriers (Bostanudin, 44 
Arafat, Sarfraz, Górecki, & Barbu, 2019; A. Lalatsa et al., 2015; Toman et al., 2015). Due to 45 
its low cost, widespread availability and ease of chemical modification, chitosan (CS) has been 46 
one of the most intensively studied polysaccharides for brain drug delivery applications, 47 
demonstrating indeed very promising results (A. Lalatsa et al., 2015; Lien et al., 2012; Toman 48 
et al., 2015). Rationalised by the ability of short chain alkylglycerols  to enhance drug access 49 
into the brain in vivo when administered intracarotidally (Erdlenbruch et al., 2003), dextran 50 
and chitosan have been previously modified with alkylglycerols and formulated into 51 
nanoparticles, which were shown to be taken up by endothelial brain cells and to increase drug 52 
permeability  in vitro and in vivo (Boussahel et al., 2017; Ibegbu, Boussahel, Cragg, Tsibouklis, 53 
& Barbu, 2017; Lien et al., 2012; Molnár, Barbu, Lien, Górecki, & Tsibouklis, 2010; Toman 54 
et al., 2015). In contrast to chitosan, polysaccharides of similar generic features but lacking a 55 
ionisable amino group that can negatively impact on the nanomedicines’ colloidal stability, 56 
such as pullulan (PUL) and guar gum (GG), have been less investigated for their potential in 57 
similar drug delivery applications (Singh, Kaur, Rana, & Kennedy, 2017). Also, to our 58 
knowledge, no comparative investigations into the characteristics and in vitro performance 59 
(such as drug loading, brain cells uptake and permeability) of different polysaccharides have 60 
been reported.  61 
Investigating the hypothesis that nanomedicines based on amphiphilic pullulan and 62 
guar gum can provide improved characteristics relevant to brain drug delivery applications 63 
compared to similarly-modified chitosan-based materials, we describe here the preparation and 64 
characterisation of colloidal formulations obtained from novel butylglyceryl-modified PUL 65 
and GG and loaded with a range of model actives (Doxorubicin, Rhodamine B, Angiotensin 66 
II). Results of in vitro investigations comparing the interactions of these nanocarriers with 67 
mouse brain endothelial cells (bEnd3) in terms of cytotoxicity, cellular uptake and BBB model 68 
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membrane permeability, relative to butylglyceryl-modified CS nanoparticles, are also 69 
presented. 70 
 71 
2. Materials and methods 72 
2.1. Materials 73 
Low molecular weight (MW) chitosan (MW 50–190 kDa; 75-85% deacetylation; cat. 74 
no. 448869; batch no. MKBD0020), pullulan (MW 100 kDa; cat. no. 91335; batch no. 75 
BCBK3803V), guar gum (MW 220 kDa; cat. no. G4129; batch no. 041M0058V), 76 
dimethylformamide (DMF; anhydrous, 99.8%), dimethyl sulfoxide (DMSO; anhydrous, ≥ 77 
99.9%), nbutylglycidyl ether (BGE; reagent grade 95%), potassium tert-butoxide (t-BuOK; 78 
reagent grade > 97%), phthalic anhydride (reagent grade ≥ 99.9%), sodium tripolyphosphate 79 
(TPP), sodium hydroxide (NaOH), Span 80, glycerol (reagent grade ≥ 99.5%), glutaraldehyde 80 
(25% in H2O; cat. no. G6257), Rhodamine B base (Dye content 97%), Angiotensin II human 81 
(HPLC grade ≥ 93%), Triton X-100, Hydrocortisone (HPLC grade ≥ 98%), Adenosine 3’,5’-82 
Cyclic Monophosphate (HPLC grade ≥ 98.5%) and Fluorescein Isothiocyanate (FITC) labelled 83 
dextran (MW 500 kDa) were sourced from Sigma Aldrich (Gillingham, UK).  84 
Hydrazine monohydrate, acetic acid, dimethylsulfoxide (DMSO, analytical grade), and 85 
dichloromethane (DCM) were purchased from Fisher Scientific (Loughborough, UK). 86 
Doxorubicin was obtained from Carbosynth (Compton, UK). Texas Red-X succinimidyl ester 87 
(mixed isomers), Texas Red-X dichlorotriazine, Dulbecco’s Modified Eagle Medium (DMEM) 88 
media, NucGreen Dead 488 and TrypLE Express were sourced from Life Technologies Ltd. 89 
(Paisley, UK). Phosphate Buffered Saline (PBS) was purchased from Gibco (Paisley, UK). 90 
Forskolin and RO-20-1724 were obtained from Enzo Life Sciences (Exeter, UK).  91 
 92 
2.2. Synthesis and characterisation of butylglyceryl-modified polysaccharides 93 
The synthesis was adapted from methods described in the literature (Bostanudin et al., 94 
2019; Molnár et al., 2010), with some modifications. Briefly, an alkaline solution of 95 
polysaccharide (either 2.78 mmol GG, 3.05 mmol PUL or 4.39 mmol phthaloylated CS, 96 
dissolved in either water, DMSO, or DMF, respectively) was reacted with n-butylglycidyl ether 97 
in different ratios (3–114 mmol, Figure 1). The reaction mixture was left stirring overnight 98 
then purified by washing (x3) with DCM and/or dialysis (MWCO 3.5 kDa, Medicell Ltd, 99 
London, UK) against deionised water (10 L; 9 changes over 72 h) prior to lyophilisation. All 100 
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materials were characterised by 1H-NMR spectroscopy using a JEOL Eclipse 400+ instrument 101 
(JEOL, Welwyn Garden City, UK; 400 MHz) and the degree of substitution (DS) was 102 
calculated from the 1H-NMR spectra. FT-IR spectra were recorded on a Nexus Euro infrared 103 
spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) and Gel permeation 104 
chromatography (GPC) was performed using a Waters Alliance GPC 2000 system (Waters 105 
Corporation, Milford, MA, USA) (details in the Supplementary Materials) 106 
 107 
2.3. Formulation of butylglyceryl-modified guar gum nanoparticles  108 
Span 80 (0.4 g) solution in DCM (3.33 mL) was added to a butylglyceryl-modified GG; 109 
GG-OX4 solution (10 mL) of specific concentration (0.5–2% w/v; different DS) under stirring. 110 
Glycerol (1 mL) was added, followed by glutaraldehyde (1 mL; 3% v/v) under stirring and was 111 
left stirring overnight prior to ultracentrifugation (x3 ultracentrifuge; Beckman Coulter, High 112 
Wycombe, UK; 70.1 Ti rotor; 164,391 g; 30 min); the pellet was washed three times with 113 
deionised water and freeze-dried, affording nanoparticles as white powder (55–65% yield).  114 
2.4. Formulation of butylglyceryl-modified pullulan nanoparticles  115 
Butylglyceryl-modified PUL solution; PUL-OX4 in DMSO (2 mL) at varying 116 
concentrations (1–10 mg/mL; different DS) was added to ultrapure water (8 mL) under stirring. 117 
The nanoparticles were dialysed (MWCO 12-14 kDa, Medicell Ltd, London, UK) against 118 
deionised water (10 L; 9 changes over 72 h) and lyophilised, affording nanoparticles as beige 119 
powder (yields 76–83%).  120 
2.5. Formulation of butylglyceryl-modified chitosan nanoparticles  121 
Sodium tripolyphosphate (2 mL) aq. solution at varying concentrations (0.1–0.3 122 
mg/mL) was introduced dropwise (1 mL/min) under stirring to butylglyceryl-modified chitosan 123 
solution; CS-OX4 (1.07–2.5 mg/mL; various DS) in aq. acetic acid (1% v/v, 6 mL). The 124 
nanoparticles were ultracentrifuged (164,391 g; 30 min), washed (x3) with deionised water, 125 
and lyophilised, affording nanoparticles as beige powder (yields 16–45%). 126 
2.6. Morphological characterisation 127 
The nanoparticles diameter was determined by dynamic light scattering (DLS) using a 128 
Malvern ZetasizerNano ZS instrument equipped with a 633 nm He-Ne laser (173° scattering 129 
angle) (Malvern Instruments Ltd., Worcestershire, UK), calibrated by 100–400 nm polystyrene 130 
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latex standard beads and DTS 1050 latex beads (Malvern Instruments Ltd). Samples were 131 
analysed (x3) at 25 °C and the results were expressed as Z-average mean and polydispersity 132 
index (PDI). Electrophoretic mobility measurements were conducted using the same 133 
instrument to determine the ZP. Investigation on nanoparticles stability at varying pH values 134 
(3–8.5) was performed employing a Multi-Purpose Titrator-2 instrument (Malvern Instruments 135 
Ltd.). The nanoparticles were redispersed (0.5 mg/mL) in an ultrapure water and the pH was 136 
adjusted with NaOH solution (0.005 M), and HCl (0.05 M); the diameter and ZP were 137 
measured at 0.5 pH increments. Complementary size determination was conducted using a 138 
Nanoparticle Tracking Analysis (NTA) LM-14 instrument (Malvern Instruments Ltd.) 139 
equipped with a 532 nm green laser at 25 °C. 140 
Scanning Electron Microscopy (SEM) was performed by depositing aqueous 141 
nanoparticles dispersion (5 mg/mL) onto a metallic stub prior to coating with Au/Pd under 142 
argon using a Q150RES sputter coater (Quorum Technologies Ltd., Ashford, UK), and imaged 143 
using a JEOL-JSM-6060LV SEM Microscope (JEOL). For Transmission Electron Microscopy 144 
(TEM), aq. dispersion (5 mg/mL) was placed onto the TEM copper grid surface (3.0 mm, 200 145 
mesh, coated with Formvar film), stained with 2% (w/v) uranyl acetate staining solution and 146 
imaged with a JEOL JEM 2100 TEM Microscope (JEOL). 147 
2.7. Model actives loading and release studies 148 
 A solution of either Rhodamine B (0.5 mL; 0.037 mg/mL in DMSO), Doxorubicin (0.5 149 
mL; 0.4 mg/mL in DMSO) and Angiotensin II (1 mL; 0.1 mg/mL in deionised water) were 150 
mixed with polymer solution during nanoparticles preparation via various techniques (section 151 
2.3−2.5). The nanoparticles were ultracentrifuged (164,391 g; 30 min); the pellets were 152 
lyophilised and weighed; the supernatant was measured for the unbound model actives amount 153 
by UV/Vis spectroscopy measurements employing a Lambda 650 Ultra Violet/Visible 154 
Spectrometer (Perkin Elmer, Buckinghamshire, UK; measuring at 544 nm for Rhodamine B; 155 
486 nm for Doxorubicin). For Angiotensin II detection, HPLC analysis was performed using 156 
an Agilent 1100 series HPLC system (Agilent Technologies, Waldbron, Germany; C18 157 
reversed phase column; acetonitrile/trifluoroacetic acid (TFA) 99.9:0.1 v/v, linear gradient 158 
10−60% (0.7 ml/min); retention time = 8.32 min; lower detection limit = 25 ng/mL. The drug 159 
loading was calculated using Equation (2): 160 
 161 
𝐷𝐿 (%)  =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 𝑥 100       (2) 162 
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For the release studies, nanoparticles were re-dispersed (1.5 mg/mL) in PBS (pH 7.4; 163 
saline 0.9%), aliquots (1.5 mL) were taken and distributed into Eppendorf tubes, which were 164 
then placed in a thermostatic (37 °C) shaking water bath. At varying time points, an aliquot 165 
(700 µL) was individually removed from the supernatant and analysed using either HPLC or 166 
UV/Vis. 167 
2.8. Nanoparticles fluorescent labelling 168 
A Texas Red-X dichlorotriazine solution in DMSO (0.5 mL; 2 mg/mL) was added to 169 
either GG-OX4 in 0.1 M sodium bicarbonate buffer (10 mL; 10 mg/mL) or PUL-OX4 solution 170 
in DMSO/0.1 M sodium bicarbonate buffer (70:30 v/v; 10 mL; 10 mg/mL) under stirring. CS-171 
OX4 labelling was performed employing Texas Red-X succinimidyl mixed ester in DMSO 172 
(0.5 mL; 2 mg/mL), where it was added to the polymer dispersion in 0.1 M sodium bicarbonate 173 
buffer (10 mL; 10 mg/mL) under stirring; maintained for 1 h. Labelled GG-OX4 and PUL-174 
OX4 was precipitated with DCM, centrifuged (2,880 g; 30 min) using a Jouan B4i (Thermo 175 
Fisher Scientific), purified by either washing (x3) with DMSO for labelled CS-OX4 or dialysis 176 
(MWCO 12-14 kDa) against deionised water (10 L; 3 exchanges over 24 h) for labelled GG-177 
OX4 and PUL-OX4 and then lyophilised, affording Texas Red-labelled polymer; GG-OX4 as 178 
a purple and fluffy cotton-like material (yields 78– 81%), PUL-OX4 and CS-OX4 as a purple 179 
powder (yields 71–73% and  71–75% respectively). The degree of labelling was analysed by 180 
UV/Vis spectroscopy (measuring at 589 nm) and calculated using Equation (3):  181 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑙𝑎𝑏𝑒𝑙𝑙𝑖𝑛𝑔 (%)  =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑇𝑒𝑥𝑎𝑠 𝑅𝑒𝑑
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 ×  100   (3) 182 
2.9. Cell culture 183 
Mouse brain endothelial (bEnd3) cells were obtained from the European Collection of 184 
Cell Cultures (ECACC). The cells (passage no. 37–45) were cultured in a modified DMEM 185 
media, enriched with supplements (Table S1, Supplementary Materials). The cells were grown 186 
at 37oC with 5% CO2 under humidified atmosphere in an incubator. Trypsinisation was 187 
performed with TrypLE Express and flasks were equilibrated at 37oC for 10–15 min. The cell 188 
suspension was harvested (115 g; 5 min) using a Beoco C28A (Wolf Laboratories, Pocklington, 189 
UK) for further use.  190 
2.10. Cytotoxicity assays 191 
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Nanoparticles (50 µL; dispersed in modified DMEM at concentrations 1–10 mg/mL) 192 
were incubated with confluent bEnd3 cells (seeding 4.0 x 104). Sterile PBS and Triton-X (0.1% 193 
v/v) were used as negative and positive controls respectively. After 24 h incubation, media was 194 
replaced with MTT solution (100 µL, 1 mg/mL) and incubated (37oC) for another 1 h prior to 195 
be replaced by DMSO (100 µL) and analysed using a POLARstar OPTIMA (BMG Labtech, 196 
Aylesbury, Bucks, UK; measuring at 570 nm).  197 
2.11. Confocal microscopy analysis 198 
Nanoparticle suspension in modified DMEM (2 mL; 0.5 mg/mL) were incubated with 199 
confluent bEnd3 cells (seeding 4.0 x 104) for 3 h; cells without nanoparticles were used as a 200 
control. The cells were washed (x3) with PBS, fixed in paraformaldehyde (4% w/v; 4oC) and 201 
permeabilised with Tween 20 (0.1% v/v) prior to 15 min incubation with NucGreen Dead 488 202 
before visualisation using a confocal microscope (LSM 510 META, ZEISS, Carl Zeiss, 203 
Oberkochen, Germany; 488 nm for NucGreen and 543 nm for Texas Red).  204 
2.12. Flow cytometry analysis 205 
Doxorubicin-loaded nanoparticles (2 mL; 0.5 mg/mL in modified DMEM) were 206 
incubated with confluent bEnd3 cells (seeding 4.0 x 104) for 3 h. The cells were harvested (115 207 
g; 5 min) and redispersed in PBS (400 µL) for analysis. Cells treated with propidium iodide 208 
(1% v/v; without nanoparticles) were used as a control. Flow cytometry was performed on a 209 
four-colour multi parameter BD FACSCalibur system (BD Biosciences, Oxford, UK) equipped 210 
with a 488 nm argon gas laser and a 635 nm red-diode laser; Doxorubicin emission 211 
fluorescence was measured using a 530/30 nm filter. 212 
2.13. Fluorescent marker translocation across bEnd3 cell monolayers studies 213 
bEnd3 cells were seeded (4 x 104 cells) in a Transwell-type BBB model comprising of 214 
a sterile 24-well plate Millipore Millicell; incubated at 37oC until confluent. A specific cocktail 215 
(consisting of cAMP (250 µM), RO-20-1724 (20 µM), Forskolin (50 µM) and hydrocortisone 216 
(550 µM)) was applied and incubation continued for another 24 h. Nanoparticles (2 mg/mL) 217 
and FITC-dextran (100 µg/mL) dispersed in media were simultaneously applied to each well 218 
and the FITC-dextran concentration in the basolateral compartment was then monitored; 219 
samples (100 µL) were collected every 30 min (for 3 h) for analysis using a POLARstar 220 
OPTIMA fluorescence plate reader (BMG Labtech) (485 nm/520 nm excitation/emission 221 
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wavelengths). The apparent permeability coefficient (Papp) was calculated based on Equation 222 
(4): 223 
𝑃𝑎𝑝𝑝 (𝑐𝑚. 𝑠−1) =  
𝑑𝑄
𝑑𝑡
 ×  
𝑉𝑅
𝐴 ×𝐶𝑜 ×60
         (4) 224 
where; 225 
dQ/dt  FITC-dextran flux transported across the membrane (µg/sec) 226 
VR  basolateral volume (600 µL) 227 
A  filter insert surface area (0.33 cm2) 228 
Co  FITC-dextran initial mass concentration at the apical side (100 µg/mL) 229 
60  conversion factor (min to s) 230 
 231 
2.14. Haemolysis studies 232 
Blood was obtained from a male Wistar rat (450 g), after CO2 asphyxiation, by 233 
collection from the heart using a 21G needle into a BD Vacutainer tube (lithium heparin) and 234 
kept on ice. The red blood cells (RBC) were separated by centrifugation (Heraeus Multifuge 235 
3SR Plus; 2000 g; 10 min; 4oC); the plasma fraction was removed before washing the RBC 236 
with PBS (x3) and centrifuged (2,000 g; 10 min), before dilution with PBS (4% w/v) to yield 237 
a cell suspension. PBS and Triton-X (1% v/v) were used as negative and positive controls 238 
respectively. NPs suspensions were added (10 µL) to RBC cell suspension (190 µL) and then  239 
incubated (37 oC) for 1 h prior to centrifugation (1200 g; 10 min; 4oC); the supernatant (150 240 
µL) absorbance was measured at 570 nm using a Multiskan GO microplate reader (Thermo 241 




 ×  100  (5) 243 
 244 
2.15. Data statistical analysis 245 
Statistical analysis was performed using SPSS Statistics v.22 software (SPSS Inc., 246 
Chicago, IL, USA, 2013). Results were expressed as mean ± standard deviation (SD) values; 247 
significance was tested using analysis of variance (ANOVA), p values were set at 0.05, unless 248 




3. Results and discussion 251 
 252 
Butylglyceryl-modified polysaccharides were synthesised via a nucleophilic 253 
substitution reaction using n-butylglycidyl ether (Figure 1) as follow: GG-OX4 synthesis was 254 
achieved under strong alkaline conditions (aq. NaOH, pH 14); PUL-OX4 preparation was 255 
performed in DMSO with t-BuOK as a base; and CS-OX4 has been prepared by protecting the 256 
free amino groups with phthaloyl moieties, followed by butylglyceryl pendant chain 257 
attachment to the available polysaccharidic hydroxyl groups and phtahloyl groups removal 258 
using hydrazine (Molnár et al., 2010). Their structures were confirmed by FT-IR and 1H-NMR 259 
spectroscopy, with molecular weight between 100kDa and 300kDa as measured by GPC 260 






































































































































1. phthalic anhydride in DMF at 136 oC;
2. butylglycidyl ether + tBuOK in DMF;
3. hydrazine monohydrate in H
2
O at 100 oC.
n m n m
 265 
Figure 1. Schematic synthesis of: A) GG-OX4, B) PUL-OX4, and C) CS-OX4. 266 
 267 
GG-OX4, CS-OX4, and PUL-OX4 derivatives with different degree of substitution 268 






size of nanoparticles  was found to increase very slightly with concentration, possibly an effect 270 
due to a corresponding increase in viscosity (Chen, Mohanraj, Wang, & Benson, 2007).  271 
Reverse emulsification was employed to formulate GG-OX4 nanoparticles using 272 
glutaraldehyde as a cross-linker. Results (Table 1) indicate that GG-OX4 with lower DS values 273 
(DS 3.6, 12.6 and 33.9%) produced nanoparticles (yields 57–67%) with size in the range of 274 
145–200 nm, with good PDI (ca. 0.2) and negative ZP values (-22 to -33 mV). PUL-OX4 275 
nanoparticles with different DS and concentrations were prepared by nanoprecipitation, when 276 
nanoparticles around 120–180 nm, with good PDI (ca. 0.2) and negative ZP values (-23 to -32 277 
mV) were obtained. CS-OX4 nanoparticles were prepared by ionotropic gelation with TPP, 278 
and results suggest that the yields increased with the TPP concentration (optimum 0.2 mg/mL), 279 
yielding nanoparticles (yields ~33%) with size around 145 (measured by DLS and NTA), 280 
monodispersed (PDI=0.32) and positive ZP value (34.1 mV). The ZP was found to decrease 281 
with an increase in the TPP concentration, likely because of the negatively charged TPP.  282 
  283 
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Table 1. Characteristics of nanoparticles at varying concentrations and DS (n=3; ±SD). 284 


























145 ± 12 169 ± 9 0.22 ± 0.02 -32.7 ± 5.2 67 ± 5 
1.0 157 ± 15 17 ± 7 0.19 ± 0.02 -28.8 ± 2.9 57 ±15 
2.0 172 ± 16 200 ± 11 0.29 ± 0.03 -27.1 ± 7.0 58 ± 13 
 
12.6 
0.5 166 ± 11 166 ± 3 0.21 ± 0.09 -29.9 ± 4.6 60 ± 10 
1.0 167 ± 13 170 ± 5 0.18 ± 0.06 -23.8 ± 1.9 58 ± 8 
2.0 178 ± 9 186 ± 8 0.15 ± 0.11 -22.1 ± 3.0 62 ± 9 
 
33.9 
0.5 167 ± 11 167 ± 4 0.24 ± 0.04 -32.4 ± 6.2 61 ± 10 
1.0 176 ± 11 177.0 ± 11 0.20 ± 0.09 -25.5 ± 2.9 66 ± 11 













139 ± 22 143 ± 12 0.20 ± 0.10 -29.2 ± 2.8 79 ± 5 
5 157 ± 20 155 ± 6 0.18 ± 0.07 -27.9 ± 1.7 80 ± 4 
10 177 ± 17 182 ± 8 0.14 ± 0.06 -29.9 ± 1.4 81 ± 4 
 
58.5 
1 133 ± 16 136 ± 15 0.21 ± 0.08 -23.4 ± 1.9 76 ± 5 
5 141 ± 12 145 ± 9 0.19 ± 0.11 -28.2 ± 3.3 77 ± 7 
10 158 ± 18 163 ± 8 0.17 ± 0.02 -30.1 ± 5.2 76 ± 9 
 
77.3 
1 124 ± 23 125 ± 13 0.18 ± 0.12 -29.0 ± 4.3 82 ± 7 
5 132 ± 19 142± 12 0.17 ± 0.09 -31.9 ± 5.1 83 ± 5 










0.10 153 ± 32 172 ± 18 0.33 ± 0.10 40.2 ± 1.7 16 ± 4 
14.1 0.15 156 ± 38 153 ± 17 0.36 ± 0.09 38.2 ± 1.4 22 ± 4 
14.1  
0.20 
146 ± 34 146 ± 26 0.32 ± 0.07 34.1 ± 2.1 33 ± 4 
30.5 157 ± 28 148 ± 24 0.25 ± 0.02 33.8 ± 3.0 31 ± 4 
51.1 167 ± 32 156 ± 11 0.25 ± 0.01 31.9 ± 0.6 27 ± 3 
14.1 0.30 289 ± 23  241 ± 14 0.31 ± 0.03 31.1 ± 1.4 45 ± 7 
14.1 1.50 0.20 167 ± 31 167 ± 16 0.31 ± 0.07 32.4 ± 2.0 28 ± 3 
14.1 2.00 0.20 218 ± 17 171 ± 15 0.35 ± 0.05 33.7 ± 1.8 34 ± 3 




The stability of polysaccharide nanoparticulate suspensions was studied at various pH 286 
values in the range 3 to 8.5, with the main results being summarised in Figure 2. PUL-OX4 287 
nanoparticles demonstrated better stability compared to the other materials under investigation, 288 
showing only a slight increase in size; the diameter remained always below 200 nm, as the 289 
modified pullulan was unaffected by pH changes due to the absence of ionisable groups 290 
(Barbosa, Abdelsadig, Conway, & Merchant, 2019). For GG-OX4 nanoparticles, an increase 291 
in size and a decrease in zeta potential were noticed at pH ≤4, where acidic conditions likely 292 
catalysed additional intermolecular cross-linking between the existing hemiacetals and the 293 
hydroxyl groups present on neighbouring macromolecules, leading eventually to 294 
agglomeration (Hongbo, Yanping, Wen, & Siqing, 2016; Pal, Paulson, & Rousseau, 2009). 295 
Freshly formulated CS-OX4 nanoparticles were cationic (with zeta potential around + 30 mV), 296 
and showed a stable diameter in acidic conditions (ca. 140 nm). However, as the pH increased 297 
above the pKa value of chitosan (ca. 6.3 (Wang et al., 2006)), a significant augmentation in 298 
diameter accompanied by a noticeable loss of stability (resulting from the deprotonation of the 299 























































































Figure 2. The influence of pH on the size and zeta potential of: A) GG-OX4, B) PUL-OX4, 305 
and C) CS-OX4 nanoparticles (1 mg/mL) (n=3, ±SD). 306 
 307 
The nanoparticle morphology is exemplified in Figure 3. GG-OX4 and CS-OX4 308 
nanoparticles were found to have the tendency to agglomerate during the purification and 309 
lyophilisation stages; the larger residual fragments visible in their SEM images (ribbon-like in 310 
Figure 3a, and fibre-like in Figure 3C) are attributed to the cross-linking reactions (with 311 
glutaraldehyde and sodium tripolyphosphate, respectively) employed during the formulation 312 
of these types of nanoparticles and drying during SEM sample preparation. PUL-OX4 313 
nanoparticles showed a close to spherical morphology, in accordance with  literature (Jung, 314 
Jeong, Kim, & Kim, 2004).  SEM image indicated the CS-OX4 NPs were packed together after 315 
centrifugation and lyophilisation, which also affected their morphology. TEM images for PUL-316 
OX4 and CS-OX4 NPs confirmed their spherical-like shape. 317 
 318 
                 319 
           320 
Figure 3. SEM micrograph of lyophilised nanoparticles: A) GG-OX4 (Bar: 1µm), B) PUL-321 
OX4 (Bar: 2µm), C) CS-OX4 (Bar: 2µm), and TEM micrograph of nanoparticles from: D) 322 
PUL-OX4 (Bar: 100 nm, 2% uranyl acetate staining), and E) CS-OX4 (Bar: 100 nm, 2% 323 














































In order to monitor their fate in vitro, nanoparticles were fluorescently labelled using 326 
either Texas Red-X dichlorotriazine (for GG-OX4 and PUL-OX4) or Texas Red-X 327 
succinimidyl ester (for CS-OX4). The degree of labelling was determined as follows: 1.84% ± 328 
0.51 for CS-OX4, 5.51% ± 1.29 for PUL-OX4, and 11.98% ± 2.56 for GG-OX4 (n=3, ±SD). 329 
CS-OX4 showed the lowest degree of labelling, likely due to the heterogeneous nature of the 330 
reaction (Sadki, 2011), which was carried out in suspension. 331 
Model actives (MW 500-1000 Da, BCS class III or peptides (Benival & Devarajan, 332 
2015; Volpe, 2004)) such as Doxorubicin and Rhodamine B that are known to be effluxed (Lee 333 
et al., 1994), and Angiotensin II were employed to investigate the drug loading and drug release 334 
profiles in/from the carriers. GG-OX4 nanoparticles exhibited the highest loading for 335 
Rhodamine B (3.78% ± 0.6) and Doxorubicin (19.11% ± 1.2), while Angiotensin II showed 336 
the highest load in PUL-OX4 (8.46% ± 1.0). Other results were presented as follows: CS-OX4 337 
NPs had DL 1.38% ± 0.1, 3.56% ± 0.7, and 11.13% ± 1.6 for Rhodamine B, Angiotensin II 338 
and Doxorubicin respectively; GG-OX4 exhibited DL 6.11% ± 1.2 for Angiotensin II; and 339 
PUL-OX4 showed DL 2.11% ± 0.1 and 6.13% ± 0.8 for Rhodamine B and Doxorubicin 340 
respectively (n=3, ±SD). Overall, nanoparticles with negative zeta potential (GG-OX4 and 341 
PUL-OX4) demonstrated higher loading for positively-charged actives (Rhodamine B and 342 
Doxorubicin (Janes, Fresneau, Marazuela, Fabra, & Alonso, 2001; Selvam et al., 2008); 343 
Angiotensin II net charge +1.4) compared to CS-OX4 (with the only exception of 344 
Doxorubicin). The covalent cross-linking of GG-OX4 NPs with glutaraldehyde is likely to have 345 
contributed positively to their good loading degree performance (George, Shah, & Shrivastav, 346 
2019) when compared to the other two modified polysaccharides.  347 
A similar release profile was observed for all types of nanoparticles (Figure 4), where 348 
an initial burst was followed by a plateau; this can be explained by the rapid release of the drug 349 
adsorbed on the surface (Fu & Kao, 2010; Ottenbrite & Kim, 2000) and the porous structure 350 
of the polymer matrix resulted from the lyophilisation. Interestingly, a delayed release of 351 
almost 1 h and a very slow release afterwards were observed in all cases for Doxorubicin, 352 
possibly because of a combined effect of a lower drug solubility in the saline employed as 353 
release medium and stronger drug interactions with the matrix (especially for cross-linked 354 










Figure 4. Release profiles of: A) Rhodamine B, B) Angiotensin II, C) Doxorubicin from loaded 363 
nanoparticles (1 mg/ml) in PBS (pH 7.4; saline 0.9%) (n=3, ±SD). 364 
 365 
The obtained drug release data were fitted in Higuchi, Hixon-Crowell and Korsmeyer-366 
Peppas kinetic models, and the quality of the fit was evaluated using the squared correlation 367 
coefficient (R2). Doxorubicin release was found to be well described by the Korsmeyer-Peppas 368 
model, which indicated it is controlled by Fickian diffusion (n < 0.5), in contrast to the slow-369 



























































































micelles (Xie, Du, Yuan, & Hu, 2012). Angiotensin II release from GG-OX4 and PUL-OX4 371 
NPs can be well described by the Higuchi’s model, and it was found to be controlled only by 372 
drug diffusion. For CS-OX4 NPs, the best fit was found with the Korsmeyer-Peppas model, 373 
which indicated the release was controlled by non-Fickian transport (n > 0.5), possibly through 374 
a combination of swelling and diffusion controlled release (Gulati, Nagaich, & Saraf, 2013). 375 
The Korsmeyer-Peppas model was the best fit for Rhodamine B release from GG-OX4 (n < 376 
0.5; Fickian diffusion), CS-OX4 (n > 0.5; non-Fickian diffusion), and  PUL-OX4 NPs (n > 1; 377 
super case II transport  involving matrix swelling (Sahoo, Chakraborti, & Behera, 2012)).  378 
An MTT assay was employed to study cytotoxicity of nanoparticles at different 379 
concentrations (1–10 mg/mL), using PBS and Triton-X (0.1% v/v) as controls. The results 380 
(Figure 5) showed that for application relevant concentrations (< 2 mg/mL) the cytotoxicity 381 
was not significant compared to the PBS control, where nanoparticles showed 85% cell 382 
viability. An increased cytotoxicity was observed however at higher concentrations  (≥ 4 383 
mg/mL), where the cell viability decreased below 75%, similar to the results reported for 384 
nanoparticles prepared from dextran modified with alkylglycidyl ether (Toman et al., 2015). 385 
The LC50 (lethal concentration 50) on bEnd3 cells was determined, it was found that 386 
PUL-OX4 NPs exhibited the lowest toxicity (LC50 9.48 ±0.98 mg/mL), followed by GG-OX4 387 
(LC50 8.84 ±0.76 mg/mL), with CS-OX4 showing the highest toxicity (LC50 7.30 ±0.77 388 




















Figure 5. Nanoparticles relative cytotoxicity against bEnd3 cells: A) PUL-OX4, B) CS-OX4, 394 
and C) GG-OX4. bEnd3 cells incubated with nanoparticles (1–10 mg/mL); PBS and Triton-X 395 
(0.1% v/v) as controls (n=36, ±SD). 396 
 397 
The interactions of nanoparticles with bEnd3 cells was investigated further using 398 
confocal microscopy and employing Texas Red-labelled nanoparticles (Figure 6). Results 399 
suggest the NPs  were taken up by cells and localised in the cytoplasm, appearing not to enter 400 
the nucleus), as previously found with butylglyceryl-modified chitosan nanoparticles (Lien et 401 
al., 2012); the uptake is suggested as being triggered via caveolar/clathrin-mediated 402 
endocytosis (Petros & DeSimone, 2010). Aggregation of nanoparticles outside cells and at the 403 
interface with the cell membranes was observed for CS-OX4,  due to a lower stability of CS-404 
OX4 formulations at pH 7.4 combined with the effect of the interactions between positively-405 
charged nanoparticles and negatively-charged cell membrane.  406 
Results obtained from flow cytometry recorded a higher than 85% uptake. PUL-OX4 407 
nanoparticles (99.32%) exhibited the highest and CS-OX4 showed the lowest (87.88%; likely 408 
because of nanoparticles clustering, evidenced by the stability and confocal microscopy 409 






























                                      412 
Figure 6. Confocal microscope images of bEnd3 cells treated with Texas Red-labelled 413 
nanoparticles (in red) from: A) PUL-OX4, B) GG-OX4, and C) CS-OX against black 414 
background. bEnd3 cells treated with NucGreen Dead 488 (in green; without nanoparticles) 415 
was used as a control (D) – Bar:  10 µm.  416 
 417 
  418 
 The effect on bEnd3 cells permeability was investigated using a Transwell-type BBB 419 
model comprising of a confluent bEnd3 cells monolayer enriched with a barrier enhancing 420 
formula (Lien et al., 2012); FITC-dextran (500 kDa) as a fluorescent marker. The longer the 421 
incubation time, the higher the permeability as noted for CS-OX4 and PUL-OX4 showing a 422 






Figure 7. FITC-DEX translocation through bEnd3 cell monolayers following treatment with 427 
nanoparticles (2 mg/mL) prepared from either native polysaccharides or butylglyceryl-428 
modified polysaccharide: A) CS-OX4, B) PUL-OX4, and C) GG-OX4. FITC-dextran and 429 
Triton-X (0.2 %) were employed as controls (n=5, ±SD). 430 
 431 
The results of permeability studies (summarised in Table 2) indicated that the FITC-432 
dextran paracellular transport across the bEnd3 monolayer increased with the DS; PUL-OX4 433 
(DS 77.3%) showed the highest permeability enhancing effect (Papp value of 5.64 x 10
-5 at 3 434 
h); this value is higher than previously reported  for alkylglyceryl-modified dextran with DS 435 
130–142%; (1.5–1.6 x 10-7; (Toman et al., 2015). No significant toxicity was induced at the 436 
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model membrane leaks associated with cell death. A concentration dependent effect was 438 
observed, however the trend was inconsistent for GG-OX4 (possibly because of the low DS of 439 
GG-OX4 used). 440 
 441 
 442 
Table 2. Permeability coefficients (Papp) calculated from experiments using mouse bEnd3 cells 443 
treated with nanoparticles (2 mg/mL) at 3 h incubation time. FITC-DEX and Triton-X as 444 
controls (n=5, ±SD). 445 
Material Degree of 
substitution 
(%) 
Concentration Papp  3 hours 
FITC-DEX - 100 µg/mL (3.28 ± 0.09) x 10-5 
CS 0 2.0 mg/mL (3.21 ± 0.04) x 10-5 
CS-OX4 
 
14.1 0.5 mg/mL (3.55 ± 0.14) x 10-5 
30.5 0.5 mg/mL (4.11 ± 0.25) x 10-5 




47.0 2.0 mg/mL (4.55 ± 0.19) x 10-5 
77.3 0.5 mg/mL (4.64 ± 0.13) x 10-5 
2.0 mg/mL (5.64 ± 0.09) x 10-5 
GG 0 2.0 mg/mL (3.38 ± 0.20) x 10-5 
GG-OX4 12.6 0.5 mg/mL (3.36 ± 0.23) x 10-5 
2.0 mg/mL (3.56 ± 0.18) x 10-5 
Triton-X - 0.2 % v/v (6.97 ± 0.33) x 10-5 
 446 
 447 
Rationalised by the fact that most of the therapeutic applications are intravenous-based, 448 
a haemolysis study was performed in order to investigate the potential toxicity of nanoparticles 449 
towards red blood cells, RBC (Figure 8); the NP concentration effect on the RBC lysis was 450 
also studied. Results indicated no toxicity at concentrations below 12 mg/mL, showing less 451 
than 10% haemolysis compared to the PBS control. A certain degree of haemolysis was found 452 
however with increasing the concentration further, and calculated LC30 values (19.87 mg/mL, 453 
18.01 mg/mL, and 13.95 mg/mL for PUL-OX4, GG-OX4, and CS-OX4, respectively) 454 
indicated that PUL-based NPs exhibit the least haemolytic effect. In contrast, at high 455 
concentrations, CS-OX4 nanoparticles were found to induce the strongest haemolytic effect, 456 
likely due to interactions between positively-charged chitosan and negatively-charged cell 457 







Figure 8. Haemolysis test results using rat RBC exposed to butylglyceryl-modified 463 
nanoparticles of varying concentrations. RBC suspension mixed with PBS or Triton-X (1%) 464 
were used as controls (n=3; ±SD).  465 
 466 
 467 
4. Conclusions 468 
 469 
Amphiphilic butylglyceryl derivatives of guar gum, pullulan, and chitosan (prepared 470 
via modification with n-butylglycidyl ether) can be formulated using various methods into 471 
nanogels (120–200 nm diameter) to be employed as drug carriers. However, only PUL-OX4 472 
colloidal formulations demonstrated acceptable stability over the whole range of pH tested (3 473 
- 8.5).  474 
GG-OX4 NPs showed the highest loading capacity for high molecular weight model 475 
actives that are known to be effluxed (such as Rhodamine B and Doxorubicin), while PUL-476 
OX4 NPs were found to perform better for high molecular weight and hydrophilic 477 
biomacromolecules such as Angiotensin II peptide; the drug release profiles can be best 478 
described by either Korsmeyer-Peppas or Higuchi equations, and showed in all cases an initial 479 
burst discharge followed by a gradual release phase.  480 
PUL-OX4 NPs demonstrated the lowest cytotoxicity (i.e. highest LC50 value, as 481 
determined by MTT) and the weakest haemolytic effect. All NPs were taken up by bEnd3 brain 482 
endothelial cells, with PUL-OX4 NPs showing the highest uptake. The presence of 483 
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based BBB model membranes, with PUL-OX4 nanoparticles showing the highest drug 485 
permeability enhancing effect. Overall, our results suggest that PUL-OX4 nanoparticles would 486 
warrant further development as they demonstrate most promising characteristics for potential 487 
use in brain drug delivery applications. 488 
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